Compare ABRDN Physical Gold Shares ETF (SGOL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.1× ABRDN Physical Gold Shares ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SGOL | VRTX | |
|---|---|---|
Market Cap | $7.03B | $127.55B |
Volume | 2,350,550 | 1,487,944 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $557.96 |
52-Week Low | $37.54 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL is trading at $39.02, down 1.66% with bearish technical signals dominating across moving averages and oscillators. The stock faces significant resistance at current levels with all support and resistance clustered around $39. Recent market sentiment reflects pressure from rising Treasury yields and Federal Reserve policy uncertainty, though some technical indicators like the 12-day RSI at 24.81 suggest potential oversold conditions.
The outlook remains challenging with persistent bearish momentum, though the deeply oversold RSI reading indicates potential for near-term stabilization. Investment opportunities exist for contrarian investors seeking gold exposure amid inflation concerns, while risks include continued pressure from rising interest rates and dollar strength that could push prices lower.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
